TNF and inflammatory bowel disease: With the SARS-CoV-2 vaccines, concerns emerged over the impact of these immune-modulating therapies, particularly tumor necrosis factor inhibitors in patients with IBD in generating effective immune responses, because the initial efficacy trials did not include individuals on immunomodulating agents.